CRO Concept Life Sciences has officially opened its expanded integrated drug discovery facilities at its Chapel-en-le-Frith site in the U.K. This significant expansion consolidates chemistry, ADMET, and screening biology capabilities, now supported by a team of 130 scientists on site. According to a company spokesperson, this development marks a pivotal milestone in Concept’s mission to expedite the creation of life-changing therapies, thereby enhancing its capacity to deliver streamlined drug discovery services that facilitate early-stage innovation through efficient workflows and problem-solving.
The newly expanded facilities are designed to offer custom-fit drug discovery solutions across various modalities and therapeutic areas, which is anticipated to generate high-value life sciences job opportunities in the Manchester and Sheffield regions. Jonathan Critchley, chief financial officer at Concept Life Sciences, highlights that the headquarters has become one of the U.K.’s largest drug discovery research sites.
Critchley emphasizes, “This expansion of our facilities strengthens our ability to turn breakthrough science into viable, fundable, and clinically impactful therapies through our integrated drug discovery capabilities.” As a client-centric CRO with scientific and regulatory expertise, Concept Life Sciences aims not only to deliver scientific results but also to provide tailored, solution-oriented approaches that assist early-stage research companies in overcoming unique drug discovery challenges.
Start your 7-day trial and see what the database can do →
